复发DLBCL部分缓解后:自体移植与CAR-T治疗的疗效比较
本研究基于CIBMTR注册数据库,比较自体造血干细胞移植(auto-HCT)与阿基仑赛(axi-cel)CAR-T治疗在挽救化疗后达部分缓解(PR)的复发DLBCL患者中的疗效。多因素分析显示auto-HCT组复发/进展风险显著更低(HR=1.49,P=.01),总生存更优(HR=1.63,P=.008),支持auto-HCT作为适合移植患者的标准治疗。
要点
- PR后auto-HCT较CAR-T显著降低复发/进展风险(HR=1.49,P=.01)。
- PR后auto-HCT较CAR-T显著改善总生存(HR=1.63,P=.008)。
- 2年无进展生存与100天非复发死亡率两组无差异。
核心结论
- 挽救化疗后达PR的DLBCL患者中,auto-HCT较CAR-T复发率更低且总生存更优。
- 数据支持auto-HCT作为适合移植的PR患者的标准治疗。
研究设计与样本
- 基于国际血液与骨髓移植研究中心(CIBMTR)注册数据库的回顾性队列研究。
- 纳入2013-2019年接受auto-HCT或2018-2019年接受阿基仑赛CAR-T且CT或PET示PR的成人DLBCL患者。
- 采用单因素和多因素回归模型比较两组临床结局,并校正相关基线与临床因素。
主要发现
- 单因素分析:2年无进展生存auto-HCT组52% vs CAR-T组42%(P=.1),无差异。
- 单因素分析:100天非复发死亡率auto-HCT组4% vs CAR-T组2%(P=.3),无差异。
- 单因素分析:2年复发/进展率auto-HCT组40% vs CAR-T组53%(P=.05),auto-HCT更低。
- 单因素分析:2年总生存auto-HCT组69% vs CAR-T组47%(P=.004),auto-HCT更优。
- 多因素分析:auto-HCT与更低的复发/进展风险(HR=1.49,P=.01;数值指向CAR-T)和更优总生存(HR=1.63,P=.008)相关。
临床怎么用
- 对挽救化疗后达PR且适合移植的复发DLBCL患者,可优先考虑auto-HCT巩固。
- CAR-T治疗仍可作为不适合移植或auto-HCT不可行患者的选项。
局限性
- 回顾性注册数据库研究,存在选择偏倚和未测量混杂可能。
- auto-HCT与CAR-T队列纳入时间窗不同(2013-2019 vs 2018-2019)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The relative efficacy of autologous hematopoietic cell transplant (auto-HCT) vs chimeric antigen receptor T-cell (CAR-T) therapy in patients with diffuse large B-cell lymphoma (DLBCL) who achieve a partial remission (PR) after salvage chemotherapy is not known. Using the Center for International Blood & Marrow Transplant Research registry database, we identified adult patients with DLBCL who received either an auto-HCT (2013-2019) or CAR-T treatment with axicabtagene ciloleucel (2018-2019) while in a PR by computed tomography or positron emission tomography scan. We compared the clinical outcomes between the 2 cohorts using univariable and multivariable regression models after adjustment for relevant baseline and clinical factors. In the univariable analysis, the 2-year progression-free survival (52% vs 42%; P = .1) and the rate of 100-day nonrelapse mortality (4% vs 2%; P = .3) were not different between the 2 cohorts, but consolidation with auto-HCT was associated with a lower rate of relapse/progression (40% vs 53%; P = .05) and a superior overall survival (OS) (69% vs 47%; P = .004) at 2 years. In the multivariable regression analysis, treatment with auto-HCT was associated with a significantly lower risk of relapse/progression rate (hazard ratio = 1.49; P = .01) and a superior OS (hazard ratio = 1.63; P = .008). In patients with DLBCL in a PR after salvage therapy, treatment with auto-HCT was associated with a lower incidence of relapse and a superior OS compared with CAR-T. These data support the role of auto-HCT as the standard of care in transplant-eligible patients with relapsed DLBCL in PR after salvage therapy.
引用
- Shadman M, Pasquini M, Ahn KW, et al. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood. 2022. PMID: 34570879. doi:10.1182/blood.2021013289
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。